Operator
Good morning. My name is Michelle, and I will be your conference coordinator. At this time, I would like to welcome everyone to the Aaron s Company Fourth Quarter 2020 Earnings Conference Call. [Operator Instructions] After the speakers remarks, there will be a question-and-answer session.
I will now turn the call over to Mr. Michael Dickerson, Vice President of Corporate Communications and Investor Relations for Aaron s. You may begin your conference.
Michael P. Dickerson
Vice President, Corporate Communications & Investor Relations
Thank you, and good morning, everyone. Welcome to the Aaron s Company Fourth Quarter 2020 Earnings Conference Call. Joining me this morning are Douglas Lindsay, Aaron s Chief Executive Officer; Steve Olsen, Aaron s President; and Kelly Wall, Aaron s Chief Financial Officer.
DGAP-Ad-hoc: Berentzen-Gruppe Aktiengesellschaft / Key word(s): Dividend
Berentzen-Gruppe Aktiengesellschaft: Dividend proposal of the Executive Board for the 2020 financial year
18-Feb-2021 / 12:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Haselünne, February 18, 2021
Berentzen-Gruppe Aktiengesellschaft: Dividend proposal of the Executive Board for the 2020 financial year
The Executive Board of Berentzen-Gruppe Aktiengesellschaft (ISIN: DE0005201602), which is listed on the regulated market (General Standard) of the Frankfurt Stock Exchange, resolved at its meeting today, on the basis of the Company s preliminary, unaudited annual financial statements for the 2020 financial year, to submit to the Superv
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces Cooperation Agreement With HEALIOS K.K.
February 16, 2021 GMT
CLEVELAND (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios. The cooperation agreement is intended to reaffirm the mutual commitment to collaborative development of MultiStem in Japan.
(2)
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 806,250 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by KalVista. The offering is expected to close on or about February 16, 2021, subject to the satisfaction of customary closing conditions.